Codexis, Inc. (CDXS)

Several events have impacted Codexis' stock price in the past six months. In November 2025, Codexis announced its Q3 2025 financial results, reporting decreased revenues but also announced a Supply Assurance Agreement with Merck and organizational changes, including a workforce reduction. A leadership transition also occurred, with Dr. Alison Moore succeeding Dr. Stephen Dilly as CEO. In May 2026, Codexis reported strong Q1 2026 financial results, with increased revenues and a narrowed net loss, reiterating its full-year 2026 revenue guidance. As of May 7, 2026, Codexis' stock price was $2.58, representing a 4.88% increase over the past year and a significant increase since the beginning of 2026. In the past three months, there has been no insider buying activity, but one insider selling transaction was noted.

Demand for Codexis' products and services can experience variability, as seen in the third quarter of 2025 due to variability in customers' manufacturing schedules and clinical trial progression. Codexis anticipates that its 2026 revenue will be more heavily weighted towards the second half of the year, suggesting an uneven distribution of demand throughout the year.

Codexis, Inc. is a biotechnology company specializing in protein engineering to develop enzymes for various applications, including pharmaceuticals, fine chemicals, biotherapeutics, food and beverage, and agriculture. The company operates within the Healthcare sector and the Biotechnology industry, with its core business revolving around its proprietary CodeEvolver® platform, which engineers high-performance enzymes to initiate or accelerate chemical reactions. Major products and platforms include the ECO Synthesis™ platform, Small Molecule Pharma Biocatalysis, Biocatalysts, Pharmaceutical Intermediates, Codex Biocatalyst Panels and Kits, an enzyme therapeutic product candidate for treating phenylketonuria (PKU), and molecular biology and diagnostic applications.

Codexis, Inc. is headquartered in Redwood City, California, U.S.A., and maintains a multi-building presence in Northern California, including its headquarters, an ECO Innovation Lab, an Enzyme Innovation Hub, and an ECO GMP Manufacturing Center. The ECO GMP Manufacturing Center is expected to open in late 2027 and will expand the company's capabilities to include GMP manufacturing of siRNA and other therapeutic oligonucleotides. Codexis derives its maximum revenue from the Americas, with a broader presence in the Middle East and Africa, Europe, and Asia-Pacific (APAC).

Codexis has a reputation as a protein engineering company focused on scalable, sustainable solutions for therapeutic development, with its CodeEvolver® platform highlighted as a significant advantage. The company has a history of recognition, including multiple Green Chemistry awards. However, the company's ESG risk category was rated as "Severe" as of April 23, 2026, by Sustainalytics, and a workforce reduction in November 2025 could have had a temporary negative impact on perceptions of the company.

Codexis, Inc. is a publicly traded company on the NASDAQ Global Select Market (CDXS), with its ownership distributed among institutional investors, insiders, and the general public. Major institutional owners include Standard Life Aberdeen plc, BlackRock, Inc., and Vanguard Group Inc. Major individual and insider owners include Vivo Ventures VII LLC, Equilon Enterprises LLC, and James R. Sulat.